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ABSTRACT
Background: Occult hepatitis B virus (HBV) infection is characterized by the detection of HBV 
DNA in serum and/or in liver in the absence of detectable hepatitis B surface antigen (HBsAg). 
The reported prevalence of occult hepatitis B varies markedly among populations and according 
to the sensitivity of the HBV DNA assay. The aim of the present study was to describe the preva-
lence of occult hepatitis B among HCV-infected and non-infected blood donors in Porto Alegre, 
Southern Brazil, using a highly sensitive real time polymerase chain reaction (PCR) method. Meth-
odology: Between 1995 and 1997 a sample of 178 blood donors with two positive anti-HCV ELI-
SA tests were consecutively selected as cases, and 356 anti-HCV negative donors were selected as 
controls. Blood donors were randomly selected from eight blood centers in Porto Alegre, Southern 
Brazil, representative of the whole blood donor population. Blood samples were kept at 70°C and 
defrosted for the first time for the analysis of this report. Tests previously performed in the labora-
tory using the same real time PCR for HBV DNA had sensitivity for detecting as low as 9 copies/mL. 
Among 158 blood samples from HBsAg-negative blood donors, five were anti-HBc positive, 53 test-
ed positive for anti-HCV and 105 had anti-HCV negative. The samples analysis was performed in 
duplicate and all blood samples tested negative for HBV DNA. Conclusion: The result reflects a very 
low prevalence of occult hepatitis B in our setting.
Keywords: hepatitis B; hepatitis B virus; blood donors; seroepidemiologic studies.
[Braz J Infect Dis 2011;15(2):159-162]©Elsevier Editora Ltda.
INTRODUCTION
Occult hepatitis B virus (HBV) infection 
is a well-recognized clinical entity charac-
terized by the detection of HBV-deoxyri-
bonucleic acid (DNA) in serum and/or in 
liver in the absence of detectable hepatitis 
B surface antigen (HBsAg). Occult HBV in-
fection has been described not only in pa-
tients who have resolved an acute or chronic 
HBV infection, but also in patients without 
any serological markers of past HBV infec-
tion.1 The prevalence of occult hepatitis B 
found in 15 different studies ranged from 1 
to 95%,1 which might be accounted to dif-
ferences between endemic and not endemic 
areas, presence of risk factors and to the 
sensitivity of the HBV-DNA assay.
Hepatitis B and C coinfection is com-
monly reported all over the world and high 
coinfection rates are attributed to the viruses 
sharing the same modes of transmission and 
being endemic in some regions.2 Since this 
coinfection is highly prevalent, occult hepatitis 
B has been extensively investigated in hepatitis 
C virus (HCV) infected patients. It has been es-
timated a rate of 20-30% of occult hepatitis B in 
international studies,3 but in some areas occult 
HBV infection has not been detected.4,5
In the report by Shetty et al, the authors 
described 28% prevalence of occult hepati-
tis B based on serum samples, and 50% on 
liver specimens of a liver transplant popu-
lation.6 Association between hepatocellular 
carcinoma and high prevalence of occult 
hepatitis B raises concerns regarding the 
detection of the occult hepatitis B infection.
The aim of the present report was to de-
scribe the prevalence of occult hepatitis B 
among HCV-infected blood donors (cases) 
and non-infected controls, in Southern Bra-
zil, using a highly sensitive real-time poly-
merase chain reaction (PCR) method.
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METHODS
Ethics statement
The study was approved by the Ethics Committees of the fol-
lowing institutions invited to participate in the study: Hos-
pital de Clínicas de Porto Alegre, Santa Casa de Misericórdia 
de Porto Alegre, Hospital Moinhos de Vento, Hospital Ernesto 
Dorneles, Laboratório Marques-Pereira, Hospital Nossa Sen-
hora da Conceição, Hospital São Lucas, Hemocentro do Rio 
Grande do Sul. All participants signed a consent form in ac-
cordance to the ethical guidelines of the 1975 Declaration 
of Helsinki.
Participants 
A random sample of blood donors was selected from eight 
blood centers in Porto Alegre, Southern Brazil, between 
1995 and 1997, in order to represent the blood donor popu-
lation. Blood samples were taken from all participants for 
the pre-donation testing and a 2 mL sub-sample was kept 
apart for further analysis. From the initial sample, 178 blood 
donors with two positive anti-HCV ELISA tests were con-
secutively selected as cases, and 356 anti-HCV negative 
donors were selected as controls.
Description of procedures
The samples were centrifuged less than 4 hours after the col-
lection and frozen at -70°C. The samples were defrosted at a 
single time for the analysis of this study. All tests were car-
ried out at Simbios Biotechnology in Brazil, a reference labo-
ratory for molecular biology in our region. Sampling details 
and other results of the study were described elsewhere.7
DNA extraction method and real-time PCR detection 
assay
The DNA extraction was made as described by Kramvis 
et al.8 For phenol-chloroform DNA extraction, a 200 µL 
aliquot of serum was incubated at 70°C for 2 hours in the 
presence of 400 mg of proteinase K, 1% sodium dodecyl 
sulfate, and 2.5 mM disodium EDTA. The suspension was 
sequentially extracted with phenol and then chloroform. 
DNA was precipitated with 0.3 M sodium acetate and then 
with absolute ethanol, washed with 70% ethanol, vacuum 
dried, and then dissolved in 50 µL of best-quality water 
(BQW). The material was than exposed to GeneReleaser, 
which is a proprietary reagent that can release DNA from 
serum. Lysis is accomplished directly in the amplification 
tube in a thermocycler. A 20 µL volume of GeneReleaser 
was added to 5 µL of serum, and the extraction was per-
formed in a programmable thermal cycler according to the 
manufacturer’s directions as follows: 65°C held for 30 sec-
onds, 8°C held for 30 seconds, 65°C held for 90 seconds, 
97°C held for 180 seconds, 8°C held for 60 seconds, 65°C 
held for 180 seconds, 97°C held for 60 seconds, 65°C held 
for 60 seconds, and 80°C held until the PCR mixture was 
added. The end product (25 µL) was used as the template for 
the 100 µL first-round PCR mixture.
Real-time PCR detection assay was made as described 
by Pas et al.9 PCR primers and probe were designed using 
Primer Express software (PE Biosystems, Nieuwerkerk a/d 
IJssel, The Netherlands). Amplification was performed in 
a 50 µL reaction mixture containing 2x TaqMan Universal 
MasterMix (PE Biosystems), 45 pmol of forward primer 
(59-GGA.CCC.CTG.CTC.GTG. TTA. CA-39, nucleotides 
184 to 203), 45 pmol of reverse primer (59-GAG.AGA.AGT. 
CCA.CCM.CGA.GTC.TAG.A-39, nucleotides 273 to 249), 
15 pmol of TaqMan probe (59-FAM-TGT.TGA.CAA.RAA.
TCC.TCA.CCA.TAC.CRC. AGA-TAMRA-39, nucleotides 
218 to 247), and 10 µL of isolated DNA. Primers and probe 
were selected in the pre-S gene of the HBV genome and gen-
erated a product of 89 bp. All isolations and amplification 
reactions were performed in duplicate. After preparation of 
the reaction mixtures in 96-well plates, the plates were cen-
trifuged at 1,200 rpm for 1 min in a Rotina 48R swing rotor 
to remove small air bubbles in the vessels. Amplification and 
detection were performed with an ABI Prism 7700 Sequence 
Detection System (PE Biosystems). After incubation for 
2 min at 50°C, which enables uracil N9-glycosylase (present 
in the 23 Universal MasterMix) to inactivate possible con-
taminating amplicons, incubation for 10 min at 95°C allowed 
AmpliTaq Gold polymerase to activate and inactivate the 
uracil N9-glycosylase. The PCR cycling program consisted 
of 45 two-step cycles of 15 seconds at 95°C and 60 seconds 
at 60°C. For standardization of the real-time PCR detection 
assay, a standard curve of the plasmid ranging from 10 mil-
lion to 670 copies/mL and a run control of 30,000 copies/mL 
(CLB) were included in each run. Validation of the plasmid 
controls was done with the VQC panel (CLB).
Diagnostic properties of the test 
For clinical purposes, this technique is able to detect 
200 viral copies/mL and it has high reproducibility. For 
research purposes, we considered any viral load detected 
as a positive PCR. Previous testing performed by Simbios 
laboratory, using the same technique, detected viral loads 
as low as 9 copies/mL.
RESULTS
In this analysis, 158 samples of blood donors from one of 
the main blood centers were tested. All samples were from 
HBsAg negative participants and five blood donors tested 
positive for hepatitis B core antibodies (anti-HBc). Fifty 
three individuals tested positive for anti-HCV and 105 were 
anti-HCV negative. The analysis of samples was performed 
in duplicate and all samples tested negative for HBV-DNA. 
Since all 158 samples tested were negative, we decided to 
stop testing the remaining samples.
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DISCUSSION
The zero prevalence of occult hepatitis B among blood do-
nors, detected in our study, is far from the 28% serum HBV 
DNA prevalence among the liver transplant population re-
ported by Shetty et al.6 Our result is in accordance with other 
studies carried out in Brazil to detect HBV in serum among 
hepatocellular carcinoma patients5 and among liver trans-
plant patients.10 Even considering that occult HBV might be 
more prevalent in end-stage liver disease population, such as 
that studied by Shetty et al.,6 than in healthy blood donors, it 
was anticipated at least a few occult hepatitis B cases.
The screening procedures in the blood centers included 
an interview of candidates to donate, precluding from dona-
tion the unhealthy or high risk individuals. This screening 
might have lowered the occult hepatitis B prevalence in the 
sample in comparison to the real prevalence in the general 
population. However, HBV and HCV share routes of trans-
mission and risk factors, and blood donor candidates were 
detected as HCV cases. Even so, 53 HCV cases and 105 anti-
HCV negative controls might have not enough statistical 
power to detect a case of occult HBV. 
False-negative results obtained from HBV-DNA detec-
tion could be another reason for not finding a single positive 
case. In our study, the lacking of occult hepatitis B cases might 
not be attributed to false-negative tests. The DNA extraction 
method and the real-time PCR technique, used for HBV-DNA 
detection, is the one currently adopted in referent laboratories 
and very low viral loads have been detected in Simbios labora-
tory on another ongoing study. However, there are theoretical 
problems related to the storage of the samples. Our samples 
had been maintained frozen and stored at -70°C on average 
for seven years. There were no voluntary or involuntary thaws 
in the period, what gives our sample an additional guaranty of 
quality. Because HBV is a DNA virus, the possibility that the 
freezing time could have spoiled the samples is remote. Stud-
ies that had used samples with multiple freezing and thawing 
cycles have not had their results affected.11 
Whether individuals with occult HBV infection are at 
risk for unfavorable endpoints still is an unresolved issue. 
Considerable data suggest that occult infection may contrib-
ute to chronic liver damage,12-14 the development of hepa-
tocellular carcinoma,15-18 transmission19,20 and reactivation 
of chronic hepatitis B.21-23 Therefore, despite some contro-
versy concerning its clinical significance, improving the 
knowledge on different aspects of occult HBV infection is 
a matter of concern worldwide, as we can see by the high 
number of new published papers on this topic. Our paper 
helps researchers and clinicians to better understand how 
relevant (or not) is occult hepatitis B in our setting, and, 
probably in other low-prevalence HBV settings.
The main reasons for the differences in occult hepatitis 
B rates among studies seem to be the genuine variability on 
the hepatitis B prevalence – either occult or not – in several 
regions of the world, in regions of the same country, and ac-
cording to characteristics of the studied population. There-
fore, we believe that the result of our study reflects a true 
negative result in a sample with extremely low prevalence 
of occult hepatitis B. As our sample size (158 individuals) is 
only able to detect prevalence rates over 0.6%, we may esti-
mate from 0 to 0.6% the prevalence of occult hepatitis B in 
blood donors in southern Brazil.
Limitations
The results refer to blood samples collected 12 to 14 years 
ago, an issue that may rise concerns about how updated are 
the information we present. Considering that the prevalence 
of hepatitis B and C and their risk factors have not changed 
much in this period, we have no reason to believe the preva-
lence of occult hepatitis B would be different if more recent 
samples were tested.
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